Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Darley

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Immunotherapy Advances|September 30, 2022
De-risking clinical trial failure through mechanistic simulationLiam V Brown, Jonathan Wagg, Rachel Darley, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 29, 2020
Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT CellsAlistair Bailey, Ben Nicholas, Rachel Darley, et al.
Frontiers in Immunology|June 7, 2021
Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide RepertoirePatricia T Illing, Andy van Hateren, Rachel Darley, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Immunotherapy Advances|September 30, 2022
De-risking clinical trial failure through mechanistic simulationLiam V Brown, Jonathan Wagg, Rachel Darley, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|December 29, 2020
Characterization of the Class I MHC Peptidome Resulting From DNCB Exposure of HaCaT CellsAlistair Bailey, Ben Nicholas, Rachel Darley, et al.
Frontiers in Immunology|June 7, 2021
Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide RepertoirePatricia T Illing, Andy van Hateren, Rachel Darley, et al.
Pageof 1